News

The company said that the underwriters of the offering have exercised their over-allotment option and purchased 525,000 additional shares of common stock from the selling stockholders at the

The recombinant botulinum (rBOT) vaccine grant is for the continued development, over a three-year period, of a serotype A and B recombinant botulinum vaccine. This is the first

The future payments will be tied to revenues of the business in the two years after closing. The acquisition is expected to be completed in the third calendar

Health Canada’s decision is said to be the first marketing authorization worldwide for any Friedreich’s Ataxia therapy. The new drug will be marketed in Canada under the brand

The company has acquired Parkway for an aggregate purchase price of $2.9 million, consisting of $1.9 million in cash and $1 million of Rosetta’s ordinary shares. An additional

These findings resulted from supportive statistical analyses based on data from the pivotal Phase III clinical trial of Advexin in patients with recurrent, refractory head and neck cancer.

The Phase I trial was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest. BFPET is FluoroPharma’s

Worldwide net revenue increased 5% to $5.9 billion for the 2008 second quarter and 6% to $11.7 billion for the 2008 first half. Excluding the favorable impact of

The company reported diluted EPS of $0.41 in the second quarter of 2008, an increase of 128% compared with $0.18 in the prior-year quarter. Total revenues for the